Investor Presentation

Ref: NEPHROPLUS/SE/70 August 11, 2026 To To BSE Limited Na(cid:415)onal Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Lis(cid:415)ng Centre Through: NEAPS Sub: Investor Presentation - Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“SEBI Listing Regulations”) Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI Listing Regulations, please find enclosed Investor Presentation on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The aforesaid disclosure is also available on the Company’s website at www.nephroplus.com Yours faithfully, For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary and Head Legal Membership No.: F9895 Uzbekistan Nephrocare Health Services Limited Nepal Q1FY27 Investor Presentation August 2026 133, 197, 235 246, 156, 155 130, 207, 155 250, 221, 129 208, 234, 249 India Philippines 252, 217, 215 38,000+ Patients 217, 242, 238 254, 242, 202 550+ Clinics Kingdom of 242, 242, 242 Saudi Arabia 350+ Cities All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Nephrocare Health Services Limited (the “Company” or “NephroPlus”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly 133, 197, 235 excluded. 246, 156, 155 Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are 130, 207, 155 subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not 250, 221, 129 limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, 208, 234, 249 technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ 252, 217, 215 materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward- 217, 242, 238 looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. 254, 242, 202 All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of 242, 242, 242 accuracy, timeliness or completeness. We understand Dialysis the way no other Company does as our Cofounder Kamal Shah is on dialysis for 28+ years! ▪ Well-structured protocol- C lear Mission ▪ Holiday dialysis program driven ecosystem Patient- ExC pe en rit eri nc c e ▪ C w Acelin tl ic vic o its m d i sne g as ni eg dnn v ce i ed ro et no bm rc aer te n ioa t nte eoR pe ld ee ofi nne DD iai la yl sy is sis toC La ere adan Nd orE mn aa lb Lle CoP na vt eie nn iet’ ns c e ▪ O D Inof tf rC- oC , l H uin cHic eD ds e fa ir rnv sdi tc oDe fs o W ts su kc ih da s P e buttonhole needles for foster sense of community s painless dialysis and emotional well-being e n e s e h t ri ot en 21 2 53 4 03 6 ,, , 21 1 29 5 17 6 ,, , 12 1 23 5 95 5 n oal rE ex Pp rI en msi ug sh nt osi sDi fa oly ss ti ns ioP Pat ni i ep i tl n nilg AN”2 w- af ado n inidd 2ne 0er ”stF se ee ul GL “ik e nein tad Pe a ev ko au Mr t o ytiP cia rt ti e nn et C 208, 234, 249 u q ie vi ri a P ◼ Active Tedx speaker st 252, 217, 215 ▪ Olympic style event for 217, 242, 238 ▪ Annual guest forum dialysis guests where they Dialysis Aashayein ▪ Guests engage with 254, 242, 202 Olympiad participate in sports nephrologists, urologists, ▪ Conducted 6 Dialysis dieticians, and transplant 242, 242, 242 Olympiads across India and specialists Philippines1 Notes: HHD: Home Haemodialysis, DOC: Dialysis on Call, DoW: Dialysis on Wheels. 1. As of March 31, 2025. 2. Silver Lining: Overcoming Adversity to Build NephroPlus – Asia’s Largest Dialysis Provider. Received several awards and accolades over the years Most People Signed Up for a Kidney Screening Online in Dialysis Chain of the Year Maximum People Screened for Serum Creatinine Test One Week Awarded by ET Health world Healthcare Awards Awarded by Guinness World Records Recognized by India Book of Records June 2025 March 2025 March 2025 133, 197, 235 246, 156, 155 130, 207, 155 250, 221, 129 For the Sake of Honour Award 208, 234, 249 Innovation Award - Innovation in Health Category Best Medical Service Outsourcer - Awarded at 14th Aegis Graham Bell Awards Business Model Innovation Award Awarded by TANKER Foundation January 2016 Feb 2024 252, 217, 215 217, 242, 238 254, 242, 202 242, 242, 242 Dialysis Provider of the Year SMB Leader of the Year Excellence in Healthcare of the Republic of Uzbekistan Awarded by Lenovo i4SMB Ministry of Health, Uzbekistan February 2023 March 2023 3 Agenda 1 Operational and Financial Performance – Q1FY27 NephroPlus - Snapshot Dialysis Industry Overview Key Differentiators Operational and Financial Performance – Q1FY27 Q1 FY27 (YoY) Performance Overview Metrics Q1FY27 Q1FY26 YoY Revenue ₹ 281.8 Cr. ₹ 227.8 Cr. 23.7% Adjusted EBITDA1 ₹ 65.1 Cr. ₹ 49.8 Cr. 30.7% 133, 197, 235 Adjusted PAT2 ₹ 36.8 Cr. ₹ 26.0 Cr. 41.7% 246, 156, 155 130, 207, 155 250, 221, 129 Guests3 38,262 33,868 13.0% 208, 234, 249 252, 217, 215 Treatments 10,31,084 9,09,860 13.3% 217, 242, 238 254, 242, 202 +120 Adjusted EBIDTA Margin 23.1% 21.9% 242, 242, 242 1. EBITDA adjusted for Saudi expenses and ESOP expenses 2. PAT adjusted for Saudi expenses, ESOP expenses 3. Guests at the end of the period Q1FY27 Consolidated Profit & Loss Account Particulars Q1FY27 Q1FY26 YoY Q4FY26 QoQ Guests 38,262 33,868 13.0% 36,981 3.5% Treatments 10,31,084 9,09,860 13.3% 9,96,074 3.5% RPT 2,733 2,503 9.2% 2,667 5.2% Profit and Loss (₹ Crs) Q1FY27 Q1FY26 YoY Q4FY26 QoQ Revenue from Operations 281.8 227.8 23.7% 265.6 6.1% Cost of Materials Consumed 62.4 54.5 59.6 Employee Cost 46.6 37.5 44.3 Healthcare professional & Hospital fees 52.2 43.0 50.5 Other Expenses 55.4 42.9 55.8 133, 197, 235 Adjusted EBITDA 65.1 49.8 30.7% 55.4 17.5% 246, 156, 155 Adjus [Showing first 8,000 characters — download PDF for full document]